SCHEMBL20135441

SCHEMBL20135441

CC(C)[C@]1(c2ccc(C(=O)N3CCC(c4nc5ccccc5s4)CC3)cc2)NC(=O)NC1=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UBE2M P61081 12/20 0.63
DCUN1D1 Q96GG9 12/20 0.63
MAPT P10636 4/20 0.62
LMNA P02545 4/20 0.60
TP53 P04637 4/20 0.60
KMT2A Q03164 2/20 0.60
MEN1 O00255 1/20 0.60
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
RECQL P46063 1/20 0.60
ALDH1A1 P00352 2/20 0.53
GAA P10253 1/20 0.53
GFER P55789 1/20 0.53
TSHR P16473 2/20 0.51
POLB P06746 1/20 0.51
MAPK1 P28482 1/20 0.51
HTT P42858 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135442 1.00 UBE2M (0.63) UBE2MDCUN1D1MAPTLMNATP53
SCHEMBL20135244 0.89 UBE2M (0.55) UBE2MDCUN1D1MAPTLMNATP53
SCHEMBL20135050 0.89 UBE2M (0.55) UBE2MDCUN1D1MAPTLMNATP53
SCHEMBL20135053 0.89 UBE2M (0.55) UBE2MDCUN1D1MAPTLMNATP53
SCHEMBL20135243 0.89 UBE2M (0.55) UBE2MDCUN1D1MAPTLMNATP53
SCHEMBL20135227 0.86 MAPT (0.46) UBE2MDCUN1D1MAPTLMNATP53
SCHEMBL20135228 0.86 MAPT (0.46) UBE2MDCUN1D1MAPTLMNATP53
SCHEMBL20135682 0.85 UBE2M (0.45) UBE2MDCUN1D1MAPTLMNATP53
SCHEMBL20135680 0.85 UBE2M (0.45) UBE2MDCUN1D1MAPTLMNATP53
SCHEMBL20135208 0.83 UBE2M (0.46) UBE2MDCUN1D1MAPTLMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 UBE2M 2697/4885DCUN1D1 3076/4885MAPT 4505/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 UBE2M 2592/4885DCUN1D1 3027/4885MAPT 4265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.